

# Nicolas Aide

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2015566/publications.pdf>

Version: 2024-02-01

98  
papers

2,841  
citations

159585

30  
h-index

189892

50  
g-index

101  
all docs

101  
docs citations

101  
times ranked

3231  
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in PET/CT Technology: An Update. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 286-301.	4.6	12
2	PET/CT variants and pitfalls in malignant melanoma. <i>Cancer Imaging</i> , 2022, 22, 3.	2.8	13
3	Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors. <i>European Radiology</i> , 2022, , 1.	4.5	2
4	SPECT/CT Imaging in Hyperparathyroidism and Benign Thyroid Disorders. , 2022, , 57-71.		0
5	Feasibility of Imaging Small Animals on a 360° Whole-Body Cadmium Zinc Telluride SPECT Camera: a Phantom Study. <i>Molecular Imaging and Biology</i> , 2022, 24, 1018-1027.	2.6	1
6	Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1998-2008.	6.4	9
7	Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2573-2585.	6.4	35
8	A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers. <i>EJNMMI Research</i> , 2021, 11, 11.	2.5	6
9	Is it time to include [18F]FDG-PET/CT in the diagnostic work-up for lymph node staging in cNO vulvar cancer patients?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3043-3045.	6.4	2
10	Revisiting detection of in-transit metastases in melanoma patients using digital 18F-FDG PET/CT with small-voxel reconstruction. <i>Annals of Nuclear Medicine</i> , 2021, 35, 669-679.	2.2	13
11	New PET technologies “embracing progress and pushing the limits. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2711-2726.	6.4	35
12	EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3286-3302.	6.4	33
13	End-of-treatment <sup>18</sup> F-FDG PET/CT in diffuse large B cell lymphoma patients: $\hat{\tau}$ SUV outperforms Deauville score. <i>Leukemia and Lymphoma</i> , 2021, 62, 2890-2898.	1.3	4
14	18F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital. <i>Diagnostics</i> , 2021, 11, 1198.	2.6	1
15	JAK Inhibitor Effectiveness in Giant-Cell Arteritis With Large-Vessel Involvement Assessed by 18F-FDG PET-CT. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, .	1.3	10
16	18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects. <i>PET Clinics</i> , 2020, 15, 1-10.	3.0	20
17	PET Imaging for Immunotherapy and Radiation Therapy. <i>PET Clinics</i> , 2020, 15, xiii-xiv.	3.0	0
18	The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT. <i>Cancer Imaging</i> , 2020, 20, 68.	2.8	11

#	ARTICLE	IF	CITATIONS
19	How fast can we scan patients with modern (digital) PET/CT systems?. European Journal of Radiology, 2020, 129, 109144.	2.6	23
20	Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. European Radiology, 2020, 30, 4623-4632.	4.5	61
21	Hormonal Receptor Immunohistochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers. Frontiers in Oncology, 2020, 10, 599050.	2.8	13
22	Evaluating response to immunotherapy with 18F-FDG PET/CT: where do we stand?. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1019-1021.	6.4	14
23	HYPHYCA: a prospective study in 613 patients conducting a comprehensive analysis for predictive factors of physiological 18F-FDG anal uptake. EJNMMI Research, 2020, 10, 28.	2.5	2
24	Comprehensive analysis of the influence of G-CSF on the biodistribution of 18F-FDG in lymphoma patients: insights for PET/CT scheduling. EJNMMI Research, 2019, 9, 79.	2.5	6
25	Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 421-428.	6.4	27
26	FDG PET/CT for assessing tumour response to immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 238-250.	6.4	194
27	Combining baseline TMTV and gene profiling for a better risk stratification in diffuse large B cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 677-679.	6.4	2
28	F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 658-666.	6.4	91
29	Assessment of alteration in liver 18F-FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 941-950.	6.4	16
30	Reply to: "All that glitters is not gold" new reconstruction methods using Deauville criteria for patient reporting. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 878-881.	6.4	5
31	Uptake of Radium-223 Dichloride and Early [18F]NaF PET Response Are Driven by Baseline [18F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients. Molecular Imaging and Biology, 2018, 20, 482-491.	2.6	18
32	Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 699-711.	6.4	37
33	FDG PET-CT as a powerful tool for diagnosing and monitoring treatment outcomes of relapsing polychondritis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 669-670.	6.4	5
34	Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients?. Journal of Nuclear Medicine, 2018, 59, 1049-1055.	5.0	22
35	Optimization of a dedicated protocol using a small-voxel PSF reconstruction for head-and-neck 18FDG PET/CT imaging in differentiated thyroid cancer. EJNMMI Research, 2018, 8, 104.	2.5	6
36	Implications of reconstruction protocol for histo-biological characterisation of breast cancers using FDG-PET radiomics. EJNMMI Research, 2018, 8, 114.	2.5	23

#	ARTICLE	IF	CITATIONS
37	Reply to the Letter to the Editor from Peters et al: On the use of the liver as a reference organ for Deauville scoring in lymphoma patients and how it may be affected by liver steatosis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2233-2234.	6.4	1
38	Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction. Annals of Nuclear Medicine, 2017, 31, 125-134.	2.2	33
39	Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs). EJNMMI Research, 2017, 7, 30.	2.5	27
40	EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 17-31.	6.4	206
41	Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by <sup>18</sup> F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study). Journal of Nuclear Medicine, 2017, 58, 1045-1053.	5.0	70
42	Propranolol 18F-FDG PET/CT. Clinical Nuclear Medicine, 2017, 42, 879-880.	1.3	5
43	Repetitive 18F-FDG-PET/CT in patients with large-vessel giant-cell arteritis and controlled disease. European Journal of Internal Medicine, 2017, 46, 66-70.	2.2	46
44	Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1-3.	6.4	3
45	EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. EJNMMI Physics, 2017, 4, 17.	2.7	14
46	Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy. Nuclear Medicine Communications, 2016, 37, 348-355.	1.1	9
47	Predictive factors of 18F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?. EJNMMI Research, 2016, 6, 84.	2.5	5
48	Does PET SUV Harmonization Affect PERCIST Response Classification?. Journal of Nuclear Medicine, 2016, 57, 1699-1706.	5.0	31
49	18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2324-2335.	6.4	45
50	Patient's weight: a neglected cause of variability in SUV measurements? A survey from an EARL accredited PET centre in 513 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 197-199.	6.4	13
51	Incremental Value of a Dedicated Head and Neck Acquisition during 18F-FDG PET/CT in Patients with Differentiated Thyroid Cancer. PLoS ONE, 2016, 11, e0162482.	2.5	10
52	Unusual 131Iodine Uptake in a Joint Demonstrated by SPECT/CT in a Patient With Differentiated Thyroid Cancer. Clinical Nuclear Medicine, 2015, 40, 332-334.	1.3	1
53	Quantifying and correcting for tail vein extravasation in small animal PET scans in cancer research: is there an impact on therapy assessment?. EJNMMI Research, 2015, 5, 61.	2.5	7
54	NEMA NU 4-Optimized Reconstructions for Therapy Assessment in Cancer Research with the Inveon Small Animal PET/CT System. Molecular Imaging and Biology, 2015, 17, 403-412.	2.6	13

#	ARTICLE	IF	CITATIONS
55	Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 2072-2082.	6.4	81
56	The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria. <i>Haematologica</i> , 2014, 99, e84-e85.	3.5	22
57	Staging the axilla in breast cancer patients with 18F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1103-1112.	6.4	48
58	SPECT/CT Imaging in Hyperparathyroidism and Benign Thyroid Disorders. , 2014, , 43-59.		1
59	Diuretic 18 F-FDG PET/CT for therapy monitoring in urothelial bladder cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1818-1819.	6.4	6
60	Contrast-enhanced small-animal PET/CT in cancer research: strong improvement of diagnostic accuracy without significant alteration of quantitative accuracy and NEMA NU 4â€“2008 image quality parameters. <i>EJNMMI Research</i> , 2013, 3, 5.	2.5	9
61	Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 985-996.	6.4	107
62	18F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer. <i>Translational Oncology</i> , 2013, 6, 586-597.	3.7	17
63	F18-Choline, a Novel PET Tracer for Parathyroid Adenoma?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3111-3112.	3.6	60
64	Interobserver Agreement of Qualitative Analysis and Tumor Delineation of <sup>18</sup> F-Fluoromisonidazole and <sup>3</sup> â€“Deoxy- <sup>3</sup> â€“ <sup>18</sup> F-Fluorothymidine PET Images in Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1543-1550.	5.0	44
65	Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions. <i>Nuclear Medicine Communications</i> , 2013, 34, 521-526.	1.1	5
66	Biodistribution and imaging of [99mTc]-HYNIC-RGD in MDA-MB-231 and NTERA-2 cancer cell xenografts. <i>Nuclear Medicine Communications</i> , 2013, 34, 709-717.	1.1	6
67	Dual-Phase 99mTc Sestamibi Scintigraphy With Neck and Thorax SPECT/CT in Primary Hyperparathyroidism. <i>Clinical Nuclear Medicine</i> , 2012, 37, 223-228.	1.3	80
68	Impact of Point Spread Function Reconstruction on Thoracic Lymph Node Staging With 18F-FDG PET/CT in Nonâ€“Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2012, 37, 971-976.	1.3	53
69	Unusual Short-Term Complete Response to Two Regimens of Cytotoxic Chemotherapy in a Patient with Poorly Differentiated Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3046-3050.	3.6	18
70	The motivations and methodology for high-throughput PET imaging of small animals in cancer research. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1497-1509.	6.4	19
71	A Dual Radiologic Contrast Agent Protocol for 18F-FDG and 18F-FLT PET/CT Imaging of Mice Bearing Abdominal Tumors. <i>Molecular Imaging and Biology</i> , 2011, 13, 518-525.	2.6	5
72	<sup>123</sup> I imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 323-333.	6.4	12

#	ARTICLE	IF	CITATIONS
73	Postchemotherapy Residual Masses in Nonseminomatous Germ Cell Tumor Patients: <sup>18</sup> F-FLT PET Is Unlikely to Identify Mature Teratoma, but Imaging of Integrin Expression Could. <i>Journal of Nuclear Medicine</i> , 2011, 52, 840-840.	5.0	1
74	Postablation <sup>131</sup> I scintigraphy with neck and thorax SPECT/CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer. <i>European Journal of Endocrinology</i> , 2011, 164, 961-969.	3.7	64
75	High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 991-1001.	6.4	34
76	High-Contrast PET of Melanoma Using <sup>18</sup> F-MEL050, a Selective Probe for Melanin with Predominantly Renal Clearance. <i>Journal of Nuclear Medicine</i> , 2010, 51, 441-447.	5.0	59
77	<sup>18</sup> F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1559-1564.	5.0	47
78	High-throughput small animal PET imaging in cancer research: evaluation of the capability of the Inveon scanner to image four mice simultaneously. <i>Nuclear Medicine Communications</i> , 2010, 31, 851-858.	1.1	16
79	Incidental findings on follow-up fluorodeoxyglucose positron emission tomography studies in lymphoma patients: beware the outlier. <i>Leukemia and Lymphoma</i> , 2009, 50, 865-867.	1.3	0
80	Clinical Relevance of Single-Photon Emission Computed Tomography/Computed Tomography of the Neck and Thorax in Postablation <sup>131</sup> I Scintigraphy for Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2075-2084.	3.6	104
81	Early <sup>2</sup> -Deoxy- <sup>2</sup> -[ <sup>18</sup> F]Fluoro-d-Glucose PET Metabolic Response after Corticosteroid Therapy to Differentiate Cancer from Sarcoidosis and Sarcoid-like Lesions. <i>Molecular Imaging and Biology</i> , 2009, 11, 224-228.	2.6	38
82	Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 396-405.	6.4	20
83	Usefulness of Automatic Quantification of Immunochemical Staining on Whole Tumor Sections for Correlation with Oncological Small Animal PET Studies: An Example with Cell Proliferation, Glucose Transporter 1 and FDG. <i>Molecular Imaging and Biology</i> , 2008, 10, 237-244.	2.6	5
84	Ivory Vertebra Appearing Photopenic on Tc-99m MDP Bone Scan. <i>Clinical Nuclear Medicine</i> , 2008, 33, 479-481.	1.3	6
85	Enlarging Residual Mass After Treatment of a Nonseminomatous Germ Cell Tumor: Growing Teratoma Syndrome or Cancer Recurrence?. <i>Journal of Clinical Oncology</i> , 2007, 25, 4494-4496.	1.6	27
86	Would Patient Selection Based on Both Calcitonin Blood Level and Doubling Time Improve <sup>18</sup> F-FDG PET Sensitivity in Restaging of Medullary Thyroid Cancer?. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1574-1574.	5.0	1
87	Unusual Intratracheal Metastasis of Differentiated Thyroid Cancer Accurately Depicted by SPECT/CT Acquisition after Radioiodine Ablation. <i>Thyroid</i> , 2007, 17, 1305-1306.	4.5	14
88	Improvement of semi-quantitative small-animal PET data with recovery coefficients: A phantom and rat study. <i>Nuclear Medicine Communications</i> , 2007, 28, 813-822.	1.1	9
89	Paraneoplastic ACTH Secretion: Bronchial Carcinoid Overlooked by Planar Indium-111 Pentetrotide Scintigraphy and Accurately Localized by SPECT/CT Acquisition. <i>Clinical Nuclear Medicine</i> , 2007, 32, 398-400.	1.3	5
90	Influence of CA 15-3 blood level and doubling time on diagnostic performances of <sup>18</sup> F-FDG PET in breast cancer patients with occult recurrence. <i>Nuclear Medicine Communications</i> , 2007, 28, 267-272.	1.1	16

#	ARTICLE	IF	CITATIONS
91	Early stage spine infarct accurately diagnosed by 99m Tc-HMDP bone scintigraphy performed on a combined single photon emission computed tomography/computed tomography system correlation with magnetic resonance imaging and histopathological findings. <i>Journal of Rheumatology</i> , 2007, 34, 2121-2.	2.0	0
92	Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study. <i>Leukemia and Lymphoma</i> , 2006, 47, 2547-2557.	1.3	32
93	Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1455-62.	5.0	90
94	6-[F-18]Fluoro-l-DOPA Positron Emission Tomography in the Imaging of Merkel Cell Carcinoma: Preliminary Report of Three Cases with 2-Deoxy-2-[F-18]Fluoro-d-Glucose Positron Emission Tomography or Pentetreotide-(111In) SPECT Data. <i>Molecular Imaging and Biology</i> , 2005, 7, 257-261.	2.6	25
95	Persistent Foreign Body Reaction Around Inguinal Mesh Prostheses: A Potential Pitfall of FDG PET. <i>American Journal of Roentgenology</i> , 2005, 184, 1172-1177.	2.2	34
96	[ 18 F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 179-188.	6.4	55
97	Efficiency of [ 18 F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1236-1245.	6.4	195
98	Positron emission tomography with [18F]FDOPA and [18F]FDG in the imaging of small cell lung carcinoma: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1266-1269.	6.4	37